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S U M M A R Y
Background: There has been a growing need for colistin as a key drug for the treatment of MDR-GNB
infection. Information on colistin use in Asian population is limited.
Methods: A retrospective observational study was conducted to assess the efﬁcacy and nephrotoxicity in
critically ill adult patients who received intravenous colistin for MDR-GNB infection in the intensive care
unit (ICU) at Bach Mai Hospital in Hanoi, Vietnam. Colistin was administered according to the dosing
guideline that was based on pharmacokinetic, pharmacodynamic and toxicodynamic principles,
adjusted by body weight and creatinine clearance.
Results: Twenty-eight eligible patients were included. The mean patient age was 60  20.4 years. The
mean body weight was 53  8.6 kg. The mean daily dose of colistin was 4.1  1.6 MIU, and the mean
cumulative dose of colistin was 48.2  22.8 MIU. Colistin therapies were classiﬁed as clinically effective in 19
(67.9%) cases. Six (21.4%) patients developed nephrotoxicity during the study period according to RIFLE
criteria.
Conclusion: A personalized dosing protocol of colistin was effective, with low nephrotoxicity, among
critically ill Vietnamese patients with low body weight. Further studies are warranted for assessing the
efﬁcacy and toxicity in a larger cohort.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Multi-drug resistant gram-negative bacteria, such as MDR-
Acinetobacter baumannii, carbapenemase-producing Enterobacteria-
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).including Asia.1 Colistin, which is produced in vivo after hydrolyzation
of its prodrug colistimethate sodium, has been increasingly employed
for over a decade as a key drug for the treatment of these MDR-GNB.2
Colistin is known for its nephrotoxicity which initially resulted in
abundance of its clinical use in 1970s.2 Majority of recent studies on
the clinical use of colistin were conducted in Europe or North America,
and there has been debate on the appropriate dosing and its relation to
the efﬁcacy and nephrotoxicity of colistin.2 Information on colistin use
pertaining to the Asian population is limited. Recently, the interim
guideline to administer colistin in critically ill patients based on
pharmacokinetic, pharmacodynamic, and toxicodynamic principlesciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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administration of colistin has not been well evaluated worldwide,
even less so in Asian countries where people tend to have lower body
weight than in Europe or North America. In this study, we evaluated
the efﬁcacy and nephrotoxicity of personalized administration of
colistin in critically-ill patients admitted to ICU in Vietnam.
2. Methods
2.1. Study Design and Patient Population
This was a retrospective observational study to assess the
efﬁcacy and nephrotoxicity in critically ill patients who received
intravenous colistin at Bach Mai Hospital (BMH) between August
15, 2013 and January 15 2014. BMH has 2000 beds and serves
as a tertiary care hospital in Hanoi, Vietnam. The study was
approved by Bach Mai Hospital institutional review board.
Adult patients aged greater than 18 years were included in the
study if they were admitted to the intensive care unit (ICU) and
received intravenous colistin for hospital acquired infection due
to MDR-GNB with positive microbiological culture. Hospital
acquired infection (HAI) was determined according to CDC/NHSN
deﬁnitions4 and according to multiple physicians’ evaluation.
Patients were excluded if they were pregnant or breast-feeding
or were receiving renal replacement therapy (intermittent
hemodialysis or continuous renal replacement therapy) before
the initiation of colistin. Patients were excluded if they received
colistin for less than ﬁve days, to ensure adequate exposure to
the drug.
2.2. Microbiology
BMH has a single centralized microbiology laboratory. Standard
identiﬁcation and susceptibility testing of clinical isolates were
performed in accordance with the Clinical and Laboratory
Standards Institute (CLSI) criteria.5 The minimum inhibitory
concentrations (MICs) of collistin were determined by E-test
(Sysmex-bioMerieux, Tokyo, Japan) according to the manufac-
turer’s instructions.
2.3. Colistin administration
The colistin product used in this study was Coly-Mycin1
produced by Sanoﬁ-Aventis. Dosing of intravenous colistin was
prospectively reviewed by clinical pharmacists. The institutional
guideline for colistin dosing was as follows3:
Loading dose (Colistin Base Activity [CBA], mg) = C-Tar-
get  2  Total actual body weight (kg).
Maintenance dose (CBA, mg) = C-target  (1.5  CrCl [Creati-
nine clearance, mL/min] + 30).
Maintenance dose was initiated 24 hours after loading dose
infusion. C-target was calculated as follows. C-target was equal
to the identiﬁed colistin MIC for the causative organism of
HAI. The doses calculated based on CBA (mg) were divided by
33.3 to convert them to MIU (million international units). The
total daily dosage was divided into two doses for twice-daily
administration.
Each bottle of colistin was dissolved in 50 mL of normal saline
solution (0.9% NaCl) and was infused immediately over 30 minutes
to 2 hours following its dissolution. Clinical pharmacists rechecked
and recalculated the maintaining colistin dose according to the
patient’s measured renal function during colistin therapy. Body
weights and CrCl were measured within 2 days of colistin
administration. Nebulized colistin was not used throughout the
study period.2.4. Data Collection
The following parameters were retrieved from the medical
records of patients in the study: age, sex, weight, underlying
diseases, baseline serum creatinine concentration, Charlson’s
score,6 Acute Physiology and Chronic Health Evaluation (APACHE)
II score,7 Clinical Pulmonary Infection Score (CPIS),8 and Sequential
Organ Failure Assessment (SOFA) score on ICU admission.9 The
information on the use of other nephrotoxic drugs (NSAIDs,
furosemide, contrast agent, angiotensin-converting enzyme inhi-
bitors) was also collected.
2.5. Clinical assessment
Clinical assessments were conducted at 3 time points: the ﬁrst
was prior to using colistin; the second was after day 5 of colistin
treatment; the last point was after discontinuing colistin. Multiple
physicians involved in the patients’ care evaluated the clinical
effectiveness of colistin therapy at each time point, based on the
resolution, persistence or worsening of symptoms and signs of
infection.
2.6. Microbiological assessment
Microbiological culture samples were collected at two time
points, the ﬁrst was prior to administering colistin and the second
was after day 5 of colistin treatment. Samples were transferred to
the microbiology department, and sample culture result and MICs
were determined. Microbiological efﬁcacy was evaluated based on
the comparison of two consecutive culture results; i.e., if the
second culture was negative, then it was evaluated as microbio-
logically effective.
2.7. Nephrotoxicity assessment
Daily serum creatinine level was recorded from the ﬁrst day of
colistin therapy until discharge or death. Nephrotoxicity was
deﬁned based on the increase in the serum creatinine concentra-
tion of 50 percent as per RIFLE (risk, injury, failure, loss, and end-
stage kidney disease) criteria.10
2.8. Statistical Analysis
All analyses were performed using SPSS 20. Bivariate analyses
were performed using the Fisher’s exact test or the Chi-square test
for categorical variables and the t-test or the Mann-Whitney U test
for continuous variables. All P-values were two-sided, a p value of
less than 0.05 was considered to indicate a statistically signiﬁcant
difference. Throughout the text, the percentages displayed are the
‘‘valid percent’’, which indicates the percent excluding the missing
data from the denominator.
3. Results
During the study period, 28 eligible patients were identiﬁed.
The mean age was 60 (20.4; range: 19-88) years, and 18 (64%) were
male (Table 1). The mean body weight of the study cohort was 53
(8.6; range: 35.5-75) kg. Eight (28.6%) patients had preexisting renal
failure prior to the administration of colistin, which was deﬁned by a
serum creatinine (Scr) value > 1.2 mg/dl. The majority (n = 26, 92.9%)
of patients had ventilator-associated pneumonia (VAP), and 2 (7.1%)
patients had blood-stream infections.
Acinetobacter baumannii were most frequently isolated
(n = 24 [85.7%]; 23 from sputum, 1 from blood), followed by
Pseudomonas aeruginosa (n = 3 [10.7%]; 3 from sputum), and
Klebsiella pneumonia (n = 3 [10.7%]; 2 from sputum and 1 from
Table 1
Patient characteristics based on the clinical response to intravenous colistin therapy (n = 28)
Characteristics Whole cohort
(n = 28)
Clinically effective
(n = 19, 68%)
Clinically ineffective
(n = 9, 32%)
P value
(Effective group
vs ineffective-
treatment group)
Demographics
Age (years), mean  SD 60.0  20.4 51.8  19.6 74  12.8 0.01
Male, n (%) 18 (64.3%) 14 (73.7%) 4 (44.4%) 0.21
Body weight (kg), median (IQR),
[mean  SD]
53.5 (45.5-58.5) [53  8.6] 57 (51-59) [54.5  6.8] 49.5 (41.5-54.3) [49.8  11.4] 0.05
Charlson comorbidity index,
median (IQR)
3 (2-5) 3 (1-4) 5 (3-6) 0.03
SOFA score, median (IQR) 8 (4.3-9) 6 (4-8) 8 (8-10) 0.02
APACHE II score, median (IQR) 14 (10-17) 12 (8-17) 14 (13-17) 0.41
CPIS, median (IQR) 6 (6-8) 6 (5-7) 8 (6-8) 0.01
Length of ICU stay prior to colistin
therapy (days), median (IQR)
6 (3-11) 6 (3-9) 6 (1-16) 0.96
Severity of illness
Severe sepsis, n (%) 19 (67.9%) 11 (57.9%) 8 (88.9%) 0.20
Septic shock, n (%) 6 (21.4%) 5 (26.3%) 1 (11.1%) 0.63
Site of Infection
VAP, n (%) 26 (92.9%) 17 (89.5%) 9 (100%) >0.99
BSI, n (%) 2 (7.1%) 2 (10.5%) 0 >0.99
Microbiology
Acinetobacter baumannii, n (%) 24 (85.7%) 17 (89.5%) 7 (77.8%) 0.57
Pseudomonas aeruginosa, n (%) 3 (10.7%) 2 (10.5%) 1 (11.1%) >0.99
Klebsiella pneumonia, n (%) 3 (10.7%) 2 (10.5%) 1 (11.1%) >0.99
Colistin MIC of Acinetobacter
baumannii, mg/L, median (IQR)
0.13 (0.13-0.30) 0.13 (0.09-0.16) 0.38 (0.13-0.50) 0.02
Colistin therapy
Average daily dose (MIU),
median (IQR), [mean  SD]
4.0 (2.7-5.6) [4.1  1.6] 4.4 (3.1-6.2) [4.4  1.7] 3.2 (2.6-4.1) [3.5  1.0] 0.12
Average daily dose per kg (MIU),
median (IQR), [mean  SD]
0.08 (0.05-0.11) [0.08  0.03] 0.09 (0.06-0.11) [0.08  0.03] 0.08 (0.05-0.11) [0.07  0.03] 0.50
Total cumulative dose (MIU),
median (IQR), [mean  SD]
39 (33-57) [48.2  22.8] 50 (33-72) [54.1  24.2] 37.5 (26.5-43.5) [35.7  13.1] 0.12
Total cumulative dose per kg
(MIU), median (IQR), [mean  SD]
0.84 (0.64-1.17) [0.91  0.38] 0.86 (0.67-1.33) [0.98  0.38] 0.80 (0.4-1.13) [0.76  0.35] 0.27
Duration of colistin therapy
(days), median (IQR)
11 (8-16) 13 (9-17) 10 (8-16) 0.26
Combination therapy with
carbapenem, n (%)
25 (89.3%) 17 (89.5%) 8 (88.9%) >0.99
Use of concomitant nephrotoxic agents
Any nephrotoxic agent 11 (39.3%) 8 (42.1%) 3 (33.3%) >0.99
ACEI 1 (3.6%) 1 (5.3%) 0 >0.99
Furosemide 10 (35.7%) 7 (36.8%) 3 (33.3%) >0.99
Renal function
Pre-existing renal failure
(Scr > 1.2 mg/dl), n (%)
8 (28.6%) 5 (26.3%) 3 (33.3%) >0.99
Scr, prior to colistin therapy, mg/dl,
median (IQR), [mean  SD]
0.8 (0.8-1.43) [1.2  0.9] 0.9 (0.8-1.2) [1.1  0.6] 0.8 (0.65-2.45) [1.5  1.4] 0.63
Scr, worst during therapy, mg/dl,
median (IQR), [mean  SD]
1.05 (0.8-2.25) [1.7  1.4] 1.2 (0.8-2.3) [1.5  0.9] 0.9 (0.75-3.85) [2.1  2.2] 0.73
Scr, upon discharge from ICU, mg/dl,
median (IQR), [mean  SD]
0.9 (0.7-1.5) [1.4  1.3] 0.9 (0.7-1.4) [1.2  0.7] 0.8 (0.6-3.7) [1.9  2.1] 0.79
CrCl, prior to colistin therapy, ml/min,
median (IQR), [mean  SD]
62.3 (34.8-76.1) [62.6  37.8] 67.6 (51.7-83.5) [80  40.5] 50 (21.1-66.2) [44.9  24.8] 0.06
CrCl, worst during therapy, ml/min,
median (IQR), [mean  SD]
52 (25.5-70) [53.7  30] 61 (34-79) [60.4  31.5] 48 (16-57.5) [39.4  21.9] 0.09
CrCl, upon discharge from ICU,
ml/min, median (IQR), [mean  SD]
60 (35.8-87.3) [63.5  34.1] 64 (47-99) [71  33.6] 55 (16.5-74) [47.7  31.2] 0.08
Renal failure upon discharge
(Scr > 1.2 mg/dl), n (%)
9 (32.1%) 6 (31.6%) 3 (33.3%) >0.99
Outcome
Total ICU length of stay (days),
median (IQR)
22 (17-30) 22 (19-30) 21 (14-30) 0.40
Microbiologically effective, n (%) 15 (62.5%) 13 (81.2%) 2 (25%) 0.02
Nephrotoxicity during colistin
therapy per RIFLE criteriaa, n (%)
6 (21.4%) 5 (26.3%) 1 (11.1%) 0.63
Increase of Scr > 150% as compared
to baseline upon discharge, n (%)
3 (10.7%) 2 (10.5%) 1 (11.1%) >0.99
In-hospital mortality, n (%) 5 (17.9%) 0 5 (55.6%) <0.01
14-day mortality, n (%) 8 (28.6%) 2 (10.5%) 6 (66.7%) <0.01
Abbreviations. ACEI, Angiotensin-converting enzyme inhibitors; APACHE, Acute Physiology and Chronic Health Evaluation; BSI, blood stream infection; CBA, colistin base
activity; CrCl, Creatinine clearance; CPIS, Clinical Pulmonary Infection Score; ICU, intensive care unit; IQR, interquartile range; MIU, Million International Units; Scr, serum
creatinine; SD, standard deviation; SOFA, Sequential Organ Failure Assessment; VAP, ventilator associated pneumonia.
a RIFLE criteria.10
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0.125 mg/L, and 0.5 mg/L, respectively, and MIC ranged from
0.064-0.75 mg/L.
The mean daily dose of colistin used in the whole cohort was
4.1  1.6 MIU (136.5  53.3 mg CBA; median: 4.0 MIU [133.2 mg
CBA], IQR [interquartile range]: 2.7-5.6 MIU [89.9-186.5 mg CBA]).
The mean daily dose of colistin per kg was 0.08  0.03 MIU/kg
(2.66  1.0 mg CBA/kg; median: 0.08 MIU/kg [2.66 mg CBA/kg], IQR:
0.05-0.11 MIU/kg [IQR: 1.67-3.66 mg CBA/kg]). The mean duration of
colistin therapy was 12.5  5.2 days (range: 5-23 days), and the
mean cumulative colistin dose was 48.2  22.8 MIU [1605.1 
759.2 mg CBA)] (median: 39 MIU [1298.7 mg CBA], IQR: 33-57 MIU
[1098.9-1898.1 mg CBA]). The mean cumulative colistin dose per kg
was 0.91  0.38 MIU/kg [30.3  12.65 mg CBA/kg] (median:
0.84 MIU [27.97 mg CBA/kg], IQR: 0.64-1.17 MIU/kg [21.31-
38.96 mg CBA/kg]). In all cases, colistin was used as combination
therapy and most frequently combined with carbapenem in 25
(89.3%) cases.
Nephrotoxicity during colistin therapy was identiﬁed in 6
(21.4%) patients according to the RIFLE criteria. All six patients
identiﬁed as AKI per RIFLE criteria were categorized as ‘‘risk’’ under
RIFLE criteria. Among 8 patients with pre-existing renal failure, 3
(37.5%) developed AKI per RIFLE criteria. Among 20 patients
without pre-existing renal failure, 3 (15%) developed AKI according
to RIFLE criteria.
Concomitant nephrotoxicity agents were used in 11 (39.3%)
patients: 1 patient received angiotensin converting enzyme
inhibitor, and 10 patients received furosemide. Other nephrotoxic
agents, such as non-steroidal anti-inﬂammatory drug, vancomy-
cin, aminoglycoside, or contrast agent was not used concurrently
with colistin in any patient.
3.1. Comparison between the clinically effective-treatment group and
the ineffective-treatment group
Colistin therapies were evaluated as clinically effective in
19 cases (68%) and clinically ineffective in 9 (32%) cases. The
patients’ characteristics based on the clinical response to
intravenous colistin therapy, were summarized in Table 1. The
patients of the clinically effective-treatment group were younger
than patients without response (mean age 51.8  19.6 vs
74  12.8, p = 0.01). The patients of the ineffective-treatment group
comprised the population that showed a greater incidence of
comorbidities with higher median Charlson comorbidity index
(3 [IQR: 1-4] vs 5 [IQR: 3-6], p = 0.03) and had more organ
dysfunction indicated by higher median SOFA score (6 [IQR: 4-8]
vs 8 [IQR: 8-10], p = 0.02). The median CPIS score was signiﬁcantly
lower in the clinically effective-treatment group than in the
ineffective-treatment group (6 [IQR: 5-7] vs 8 [IQR: 6-8], p = 0.01).
The patients in clinically effective-treatment group had marginally
higher median body weight than the ineffective-treatment group
(57 [IQR: 51-59] vs. 49.5 [41.5-54.3], p = 0.05). The median MIC of A.
baumannii is lower in clinically effective-treatment group than in
ineffective-treatment group (0.13 [0.09-0.16] vs. 0.38 [0.13-0.50],
p = 0.02). The other variables, including patients’ demographics (e.g.
sex, APACHE II score, length of ICU stay prior to colistin use), severity
of illness (e.g. severe sepsis, septic shock), site of infection, and
colistin therapy (daily doses, duration, cumulative dose), and
concomitant nephrotoxic agent use were similar between two
groups. The prevalence of pre-existing renal failure deﬁned as Scr
>1.2 mg/dl prior to colistin therapy were similar between two
groups. The frequencies of the development of nephrotoxicity, which
were deﬁned by RIFLE criteria, were similar between the two groups.
No deaths were observed in the clinically effective-treatment group
during the study period; however, 5 (55.6%) patients without
response died (p < 0.01). The 14-day mortality was higher in theclinically ineffective-treatment group than the effective treatment
group (6 [66.7%] vs. 2 [10.5%], P < 0.01).
3.2. Comparison between nephrotoxicity and non-nephrotoxicity
group
Characteristics of patients who developed nephrotoxicity and
who did not develop nephrotoxicity during colistin therapy based
on RIFLE criteria were also compared (Table 2). Patients with
nephrotoxicity had higher median body weight than patients
without nephrotoxicity (57.8 [IQR: 53.8-65.3] vs. 51.3 [IQR: 43.8-
58.1], p = 0.05). However, the colistin doses were similar between
2 groups because of decreased CrCl in the nephrotoxicity group.
Duration of colistin therapy did not differ between the two groups.
Other characteristics such as age, sex, severity of illness, site of
infections were similar between the two groups. The prevalence of
pre-existing renal failure was similar between the two groups.
Outcome parameters such as microbiological and clinical effec-
tiveness, in-hospital and 14-day mortality did not differ between
the two groups.
4. Discussion
To our knowledge, this is the ﬁrst study to describe the details of
clinical experiences of colistin use in Vietnam. The vast majority of
reports regarding colistin use in clinical settings have been
published from Europe and North America, and the data on the
clinical use of colistin in Asia is scarce.
The previously reported incidences of nephrotoxicity during
colistin therapy vary from 6% to 55%,2 and depend on various
factors such as dosing, population differences (e.g. comorbidity,
severity, clinical setting), and deﬁnition of nephrotoxicity. In this
study, we used RIFLE criteria to identify nephrotoxicity, which
was validated to correlate with prognosis.11 We used only Scr
changes for applying the RIFLE criteria without reference to GFR,
because previous reports suggested that the changes in Scr
concentrations do not correlate with the percent decreases in GFR
in the RIFLE classiﬁcation.12 The incidence of nephrotoxicity in
this study (21.4%) was lower than the incidence reported in
previous studies (range: 31-54.6%) that have evaluated nephro-
toxicity during colistin therapy using RIFLE criteria.13 Patients
received relatively lower dose of colistin in our study than the
previous studies,14–17 even if their actual body weights are
considered. The mortality and prevalence of non-responding
patients were not higher in our study,14,17,18 even though
Charlson comorbidity index scores, SOFA scores, and patients’
ages in our study were apparently not lower than previous
studies.14,17,18 We used actual body weight in place of ideal body
weight since there were no obese patients in our study cohort, in
whom the dissociation between actual and ideal body weight
could be signiﬁcant.
We excluded patients if they received colistin for less than ﬁve
days to ensure adequate exposure to the drug. In our study, no
patient developed nephrotoxicity within 5 days after starting
colistin therapy. However, previous studies reported the devel-
opment of nephrotoxicity of various incidences (15.5%-100%)
within 7 days of colistin administration,15,18 and used inclusion
criteria of receiving colistin longer than 48 to 72 hours.14–18 There
was no patient who died within 5 days after starting colistin
therapy.
In this study, we used a dosing strategy including the loading
dose and maintenance dose, which was suggested by a recent
study by Garonzik et al.3 The report of Garonzik et al included
patients from Thailand; however, it also included patients from the
U.S., and thus the range was much wider than our study (median
body weight 59.1 kg [range: 30.0–106.4] vs. 53.5 kg [35.5-75]). We
Table 2
Patient characteristics based on nephrotoxicity to intravenous colistin therapy (n = 28)
Characteristics Nephrotoxicity groupa
(n = 6, 21%)
Non-nephrotoxicity group
(n = 22, 79%)
P value
(Nephrotoxicity
group vs non-
nephrotoxicity
group)
Demographics
Age (years), mean  SD 50.2  26.4 61.4  18.4 0.29
Male, n (%) 5 (83.3%) 13 (59.1%) 0.38
Body weight (kg), median (IQR), [mean  SD] 57.8 (53.8-65.3) [59.9  8.1] 51.3 (43.8-58.1) [51.1  8.0] 0.05
Charlson comorbidity index, median (IQR) 3 (0-5) 3 (2-5) 0.59
SOFA score, median (IQR) 11 (6-13) 8 (4-8) 0.09
APACHE II score, median (IQR) 13 (15-20) 14 (12-16) 0.84
CPIS, median (IQR) 6 (3-7) 6 (6-8) 0.16
Length of ICU stay prior to colistin therapy (days), median (IQR) 4 (1-7) 6 (4-12) 0.14
Severity of illness
Severe sepsis, n (%) 2 (33.3%) 17 (77.3%) 0.06
Septic shock, n (%) 3 (50%) 3 (13.6%) 0.09
Site of Infection
VAP, n (%) 5 (83.3%) 21 (95.5%) 0.39
BSI, n (%) 1 (16.7%) 1 (4.5%) 0.39
Microbiology
Acinetobacter baumannii, n (%) 4 (66.7%) 20 (90.9%) 0.19
Pseudomonas aeruginosa, n (%) 1 (16.7%) 2 (9.1%) 0.53
Klebsiella pneumonia, n (%) 2 (33.3%) 1 (4.5%) 0.11
Colistin MIC of Acinetobacter baumannii, mg/L, median (IQR) 0.13 (0.03-0.17) 0.13 (0.13-0.37) 0.31
Colistin therapy
Average daily dose (MIU), median (IQR), [mean  SD] 3.3 (2.2-5.8) [3.8  1.8] 4 (3-5.5) [4.2  1.5] 0.43
Average daily dose per kg (MIU), median (IQR), [mean  SD] 0.07 (0.04-0.1) [0.07  0.03] 0.09 (0.06-0.11) [0.08  0.03] 0.22
Total cumulative dose (MIU), median (IQR), [mean  SD] 42 (32-89.3) [57.2  33.3] 39 (33-57) [45.7  19.3] 0.70
Total cumulative dose per kg (MIU), median (IQR), [mean  SD] 0.76 (0.56-1.5) [0.96  0.54] 0.85 (0.7-1.16) [0.9  0.34] 0.96
Duration of colistin therapy (days), median (IQR) 16 (12-18) 11 (8-15) 0.11
Combination therapy (with carbapenem), n (%) 5 (83.3%) 20 (90.9%) 0.53
Use of concomitant nephrotoxicity agents
Any nephrotoxicity agent 2 (33.3%) 9 (40.9%) >0.99
ACEI 0 1 (4.5%) >0.99
Furosemide 2 (33.3%) 8 (36.4%) >0.99
Renal function
Pre-existing renal failure (Scr > 1.2 mg/dl), n (%) 3 (50%) 5 (22.7%) 0.31
Scr, prior to colistin therapy, median (IQR) 1.2 (0.8-2.0) [1.5  1.0] 0.8 (0.7-1.3) [1.2  0.9] 0.26
Scr, worst during therapy, median (IQR) 2.7 (1.3-3.7) [2.7  1.7] 1.0 (0.8-1.4) [1.4  1.2] 0.03
Scr, upon discharge from ICU, median (IQR) 1.9 (1.2-3.7) [2.4  1.8] 0.8 (0.7-1.1) [1.1  1.0] 0.02
CrCl, prior to colistin therapy, median (IQR) 62.2 (25.4-119.7) [77.4  66.6] 62.3 (37.9-76) [58.6  26.4] 0.80
CrCl, worst during therapy, median (IQR) 28.5 (13.3-89) [46.7  43.2] 54 (44.3-68) [55.6  26.4] 0.40
CrCl, upon discharge from ICU, median (IQR) 42 (17.8-81) [52.2  46.1] 61.5 (44.8-90.3) [66.6  30.7] 0.31
Renal failure upon discharge (Scr > 1.2 mg/dl), n (%) 5 (83.3%) 4 (18.2%) 0.01
Outcomes
Total ICU length of stay (days), median (IQR) 23 (19-33) 21 (16-29) 0.40
Microbiologically effective, n (%) 5 (83.3%) 10 (55.6%) 0.35
Clinically effective, n (%) 5 (83.3%) 14 (63.6%) 0.63
In-hospital mortality, n (%) 1 (16.7%) 4 (18.2%) >0.99
14-day mortality, n (%) 2 (33.3%) 6 (27.3%) >0.99
Abbreviations. ACEI, Angiotensin-converting enzyme inhibitors; APACHE, Acute Physiology and Chronic Health Evaluation; BSI, blood stream infection; CrCl, Creatinine
clearance; CPIS, Clinical Pulmonary Infection Score; ICU, intensive care unit; IQR, interquartile range; MIU, Million International Units; Scr, serum creatinine; SD, standard
deviation; SOFA, Sequential Organ Failure Assessment; VAP, ventilator associated pneumonia.
a Nephrotoxicity was deﬁned according to RIFLE criteria.10
N.G. Binh et al. / International Journal of Infectious Diseases 35 (2015) 18–2322evaluated the efﬁcacy and safety of a colistin dosing strategy,
including the loading dose and the maintenance dose,3 which was
adjusted by both body weight and CrCl, in Asian population with
lower body mass. Further studies are warranted to assess the
efﬁcacy and toxicity in a larger cohort. Due to the worldwide
spread of multi-drug resistant pathogens, a personalized approach
is crucial for the appropriate use and evaluation of efﬁcacy and
safety of colistin therapy in clinical settings.
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